References
- Mourad N, Mounier N, Brieve J, et al Clinical, biologic and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2008;111:4463–4470.
- Dogan A, Attygalle A, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 2003;121:681–691.
- Grogg K, Morice W, Macon W. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol 2007;137:416–422.
- Zhou Y, Attygalle AD, Chuang S, et al Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol 2007;138:44–53.
- Gisselbrecht C, Gaulard P, Lepage E, et al Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. 1998;92:78–82.
- Park B, Ryoo B, Lee J, et al Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007;48:716–722.
- Pautier P, Devidas A, Delmer A, et al Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999;32:545–522.
- Bruns I, Fox F, Reinecke P, Kobbe G, Kronenwett R, Jung G. Complete remission in a patient with a relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;12:1993–1995.
- Takemori N, Kodairi J, Toyoshima N, et al Successful treatment of immunoblastic lymphadenopathy-like T-cell lymphoma with cyclosporin A. 1999;35:389–395.
- Strupp C, Aivada M, Germing U, Gattermann N, Haas R. Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 2002;43:133–137.
- Hast R, Jacobsson B, Petrescu A, Hjalmar V. Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia. Leuk Lymphoma 1999;34:597–601.
- Advani R, Horwitz S, Zelenetz A, Horning S. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007;48:521–525.
- Chang S, Lu C, Chuang S. CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 2007;48:117–121.
- Dearden C. Alemtuzumab in peripheral T-cell malignancies. Cancer Biother Radiopharm 2004;19:391–398.
- Halene S, Zieske A, Berliner N. Sustainted remission from angioimmunoblastic T-cell lymphoma induced by alentuzumab. Nat Clin Pract Oncol 2006;3:165–168.
- O'Connor O, Pro B, Pinter-Brown L, et al PROPEL: results of the pivotal multicenter phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol 2009;27(Suppl.):15s (Abstract 8561).